Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera.
The seminal discovery of the JAK2V617F mutation, which is highly prevalent in Philadelphia-negative myeloproliferative disorders, now renamed neoplasms, triggered an almost unprecedented explosion of interest and data in the field. Descriptions of additional mutations in exon 12 of JAK2, at position 515 in MPL, and a number of other mutations at low frequency followed these discoveries. These advances in our understanding of molecular pathogenesis of these conditions coincided with the publication of results from two major clinical studies, ECLAP and PT-1, which contributed important clinical insights and facilitated significant correlative data collection. This article, focusing mainly upon essential thrombocythemia and polycythemia vera, reviews four major themes: the impact upon classification of these disorders considering a radical review of current terminology, and then three areas pertinent to clinical management: the indications for cytoreductive therapy in which the key targets are to reduce thrombohemorrhagic complications, relieve disease-related symptoms, and minimize the risk of transformation to secondary myeloid malignancy such as myelodysplasia, leukemia, and secondary myelofibrosis; and second reviewing current and, last, future therapeutic options, in particular interferon and JAK2 inhibitors.
Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom. Claire.Harrison@gstt.nhs.uk
Claire
C
Harrison
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000145:classification / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000145:classification / Q000235:genetics / Q000628:therapy*
D015415:Biomarkers; D047428:Protein Kinase Inhibitors; D007372:Interferons